Clinical Trial Update: Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 trial of NPI-0052 in patients with advanced solid tumor malignancies or refractory lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• NPI-0052 (Salinosporamide A)

Snippet

Sponsor: Celgene | Conditions: Cancer, Lymphomas | Phase 1 | Status: COMPLETED